Bin Lin
Papers
1
Total Citations
8
H-Index
1
About
Bin Lin is a researcher whose work has centered on the intersection of drug discovery and high-throughput screening (HTS) methodologies. His most cited paper, "High throughput screening for new drug discovery" (2020, 8 citations), provides a critical analysis of the pharmaceutical market's evolution, noting its growth from $247.9 billion in 1994 to a projected $342 billion by 1999, while positioning HTS as a transformative approach to accelerate drug development. Lin’s contributions emphasize the scalability of HTS, expanding screening capacity from thousands to hundreds of thousands of compounds, thereby revolutionizing early-stage drug discovery. Though his citation count is modest, his work offers foundational insights into the economic and technological drivers of pharmaceutical innovation. Lin’s research is particularly valuable for students and researchers exploring the integration of automation, assay development, and data analysis in drug discovery pipelines. His focus on HTS as a bridge between market demands and scientific capability underscores its enduring relevance in modern pharmacology.
Research Focus
Key Achievements
Top Papers
- 1High throughput screening for new drug discovery8 citations · 2020